Cannapharmarx AI Stock Analysis
Want to see CPMD full AI Analyst Report?
Cannapharmarx (CPMD) AI Stock Analysis
Cannapharmarx
(Other OTC:CPMD)
The score is primarily driven by weak financial performance: declining TTM revenue, deeply negative profitability, and a stressed capital structure with negative equity and debt exceeding assets. Improved TTM operating and free cash flow provides some offset, but technical and valuation inputs are largely neutral/limited due to missing indicators and a negative P/E.
Cannapharmarx (CPMD) vs. SPDR S&P 500 ETF (SPY)
Not enough price history over this period.
- Market Cap
- $1.42M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 0.08
- Revenue Growth
- -30.82%
- EPS Growth
- -26.13%
- Country
- US
- Employees
- 26
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Cannapharmarx Business Overview & Revenue Model
Company Description
CannaPharmaRX, Inc. is a Canadian enterprise actively involved in the cannabis sector. The company focuses on identifying, acquiring, and developing diverse projects for cultivating cannabis. Founded in 1998, its main offices are located in Calgary,...
How the Company Makes Money
null
Cannapharmarx Financial Statement Overview
Summary
Financials are weak overall: TTM revenue fell ~30.5% and profitability remains deeply negative (gross profit below zero with substantial operating and net losses). The balance sheet is highly stressed with persistent negative equity and debt (~$21.6M) far exceeding assets (~$7.3M). The main positive is improved TTM cash generation (operating cash flow ~$1.43M and free cash flow ~$1.48M), but it appears fragile given ongoing losses and limited implied debt-service capacity.
Income Statement
9Very NegativeBalance Sheet
6Very NegativeCash Flow
32Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.18M | 1.36M | 820.14K | 0 | 0 | 0 |
| Gross Profit | -1.35M | -2.08M | -2.94M | -65.56K | -295.00K | -14.36K |
| EBITDA | -7.36M | -3.25M | -7.53M | -1.45M | -4.91M | -2.61M |
| Net Income | -9.19M | -11.13M | -9.91M | 3.69M | -8.53M | -8.83M |
Balance Sheet | ||||||
| Total Assets | 7.29M | 7.02M | 10.84M | 11.75M | 5.41M | 114.33K |
| Cash, Cash Equivalents and Short-Term Investments | 32.04K | 1,804 | 2,156 | 650 | 2,317 | 27.77K |
| Total Debt | 21.60M | 20.65M | 14.06M | 12.94M | 14.52M | 9.02M |
| Total Liabilities | 37.47M | 37.17M | 30.65M | 23.90M | 22.76M | 13.04M |
| Stockholders Equity | -30.19M | -30.15M | -19.81M | -12.15M | -17.34M | -12.93M |
Cash Flow | ||||||
| Free Cash Flow | 1.48M | -794.62K | -1.70M | -2.36M | -1.56M | -2.42M |
| Operating Cash Flow | 1.43M | -789.10K | -1.70M | -2.27M | -1.45M | -2.41M |
| Investing Cash Flow | -61.23K | -5,519 | 0 | -80.63K | -116.00K | 493.62K |
| Financing Cash Flow | -430.98K | 794.27K | 1.70M | 2.35M | 1.40M | 1.30M |
Cannapharmarx Risk Analysis
Cannapharmarx disclosed 63 risk factors in its most recent earnings report. Cannapharmarx reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksCannapharmarx Peers Comparison
Overall Rating
YCBD43Neutral
CPMD43Neutral
XWEL39Underperform
IMCC37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | $4.03M | -1.17 | -34.25% | ― | 10.01% | 95.01% | |
| 43Neutral | $1.42M | -0.14 | 30.29% | ― | -30.82% | -26.13% | |
| 39Underperform | $4.35M | -0.08 | 317.52% | ― | -7.58% | -30.33% | |
| 37Underperform | $921.90K | -0.02 | 528.80% | ― | -35.33% | -110.11% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CPMD | Cannapharmarx | ― | ― | ― | |
| XWEL | Xwell, Inc. | 0.41 | -0.32 | -43.84% | |
| YCBD | Cbdmd INc | 0.36 | -0.16 | -30.77% | |
| LEXX | Lexaria Bioscience Corp. | 4.03 | -11.87 | -74.65% | |
| IMCC | Im Cannabis Corp | 0.50 | -45.10 | -98.91% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 20, 2026